These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 22267017)
21. Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. Ortu F; Weimer LE; Floridia M; Manconi PE Eur J Med Res; 2010 Feb; 15(2):81-3. PubMed ID: 20452889 [TBL] [Abstract][Full Text] [Related]
23. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F; J Antimicrob Chemother; 2016 Jul; 71(7):1987-93. PubMed ID: 26994089 [TBL] [Abstract][Full Text] [Related]
24. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Luque A; Hulse S; Wang D; Shahzad U; Tanzman E; Antenozzi S; Smith B Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543 [TBL] [Abstract][Full Text] [Related]
25. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354 [TBL] [Abstract][Full Text] [Related]
26. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. Funderburg NT; Andrade A; Chan ES; Rosenkranz SL; Lu D; Clagett B; Pilch-Cooper HA; Rodriguez B; Feinberg J; Daar E; Mellors J; Kuritzkes D; Jacobson JM; Lederman MM PLoS One; 2013; 8(12):e83514. PubMed ID: 24367599 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898 [TBL] [Abstract][Full Text] [Related]
28. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Spaulding A; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777 [TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P; Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224 [TBL] [Abstract][Full Text] [Related]